

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	May 12 EXTEND option available in structure searching
NEWS	4	May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in Cplus
NEWS	6	May 27 Cplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02 Cplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02 STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02 The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04 Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:02:56 ON 14 AUG 2004

=> file medline, uspatful, dgene, embase, wpids, biosis, jicst

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.21	0.21

FILE 'MEDLINE' ENTERED AT 16:03:33 ON 14 AUG 2004

FILE 'USPATFULL' ENTERED AT 16:03:33 ON 14 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:03:33 ON 14 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 16:03:33 ON 14 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:03:33 ON 14 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 16:03:33 ON 14 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'JICST-EPLUS' ENTERED AT 16:03:33 ON 14 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

=> s INGAP or islet cell neogenesis associated protein
L1 2417 INGAP OR ISLET CELL NEOGENESIS ASSOCIATED PROTEIN

=> s l1 and encoding DNA
L2 0 L1 AND ENCODING DNA

=> s l1 and DNA encoding
3 FILES SEARCHED...
L3 13 L1 AND DNA ENCODING

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 13 USPATFULL on STN
TI Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
AB The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression.

ACCESSION NUMBER: 2004:202937 USPATFULL
TITLE: Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
INVENTOR(S): Dangond, Fernando, Newton, MA, UNITED STATES
Hwang, Daehee, Seattle, WA, UNITED STATES
Gullans, Steven R., Natick, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004156826	A1	20040812
APPLICATION INFO.:	US 2003-670766	A1	20030925 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-414219P	20020927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI L.L.P., SUITE 2400, 600 CONGRESS
AVENUE, AUSTIN, TX, 78701-3271
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 7243

L3 ANSWER 2 OF 13 USPATFULL on STN

TI Methods of use of compounds with preptin function
AB The invention features methods for treating various diseases, disorders
and/or conditions, including injuries and wounds, as well as diseases,
disorders and/or conditions for example that relate to or a
recharacterized, in whole or inpart, by decreased β -cell mass,
decreased β -cell number, and/or decreased β -cell function, in
a subjects including humans and non-human animals. The methods include
administering to a subject an effective amount of one or more compounds
including preptins, preptin analogs, preptin agonists, salts thereof,
and derivatives thereof

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:184510 USPATFULL
TITLE: Methods of use of compounds with preptin function
INVENTOR(S): Cooper, Garth James Smith, Auckland, NEW ZEALAND
Buchanan, Christina Maree, Auckland, NEW ZEALAND
James, Gabriel Christopher, Auckland, NEW ZEALAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142393	A1	20040722
APPLICATION INFO.:	US 2003-632366	A1	20030731 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	NZ 2002-520536	20020801
	US 2002-400445P	20020801 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BUCHANAN INGERSOLL, P.C., ONE OXFORD CENTRE, 301 GRANT STREET, 20TH FLOOR, PITTSBURGH, PA, 15219	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2423	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 13 USPATFULL on STN

TI Method for repairing a damaged portion of a human organ
AB An organ derived from genetic material is inserted in a patient's body.
Genetic material is inserted at a selected site in the body to grow an
organ.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:94185 USPATFULL
TITLE: Method for repairing a damaged portion of a human organ
INVENTOR(S): Elia, James P., Scottsdale, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004071637	A1	20040415
APPLICATION INFO.:	US 2003-626761	A1	20030724 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-794456, filed on 27 Feb 2001, PENDING Continuation of Ser. No. US 1998-64000, filed on 21 Apr 1998, PENDING Continuation-in-part of Ser. No. US 1997-837608, filed		

on 21 Apr 1997, ABANDONED Continuation-in-part of Ser.
No. US 1994-326857, filed on 21 Oct 1994, GRANTED, Pat.
No. US 5759033 Continuation of Ser. No. US 1993-87185,
filed on 2 Jul 1993, GRANTED, Pat. No. US 5397235
Continuation-in-part of Ser. No. US 1993-53886, filed
on 27 Apr 1993, GRANTED, Pat. No. US 5372503

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gerald K. White, Esq., GERALD K. WHITE & ASSOCIATES,
P.C., Suite 835, 205 W. Randolph Street, Chicago, IL,
60606
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 13 USPATFULL on STN
TI Modified transferrin fusion proteins
AB Modified fusion proteins of transferrin and therapeutic proteins or
peptides with increased serum half-life or serum stability are
disclosed. Preferred fusion proteins include those modified so that the
transferrin moiety exhibits no or reduced glycosylation, binding to iron
and/or binding to the transferrin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31195 USPATFULL
TITLE: Modified transferrin fusion proteins
INVENTOR(S): Prior, Christopher P., Philadelphia, PA, UNITED STATES
PATENT ASSIGNEE(S): BioRexis Pharmaceutical Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023334	A1	20040205
APPLICATION INFO.:	US 2002-231494	A1	20020830 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	15780	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L3 ANSWER 5 OF 13 USPATFULL on STN
TI Immunoprotective methods for beta cell neogenesis
AB The invention is based on the disclosure provided herein that a
biologically active fragment of pancreatitis associated polypeptide can
be used to stimulate beta cell growth and at the same avoid and overcome
the T-cell mediated autoimmune attack on the pancreas. Typical
embodiments of the invention include methods of inhibiting the onset of
Type I diabetes in a mammalian subject predisposed to Type I diabetes
comprising administering to the subject a therapeutically effective
amount of a pancreatitis associated polypeptide comprising the amino
acid sequence IGLHDPTQGTEPNGE (SEQ ID NO: 3).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:300774 USPATFULL

TITLE: Immunoprotective methods for beta cell neogenesis
INVENTOR(S): Van Antwerp, William P., Valencia, CA, UNITED STATES
PATENT ASSIGNEE(S): Medtronic MiniMed, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003212000	A1	20031113
APPLICATION INFO.:	US 2003-434906	A1	20030509 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-379202P	20020509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GATES & COOPER LLP, HOWARD HUGHES CENTER, 6701 CENTER DRIVE WEST, SUITE 1050, LOS ANGELES, CA, 90045	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1834	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 13 USPATFULL on STN
TI Islet cells from human embryonic stem cells
AB This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:200963 USPATFULL
TITLE: Islet cells from human embryonic stem cells
INVENTOR(S): Fisk, Gregory J., Fremont, CA, UNITED STATES
Inokuma, Margaret S., San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138948	A1	20030724
APPLICATION INFO.:	US 2002-313739	A1	20021206 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338885P	20011207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	1597	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 13 USPATFULL on STN
TI Full-length serine protein kinase in brain and pancreas
AB The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine, etc. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing,

staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, especially relating to brain and pancreas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:140430 USPATFULL
TITLE: Full-length serine protein kinase in brain and pancreas
INVENTOR(S): Shu, Youmin, Potomac, MD, UNITED STATES
Fan, Wufang, Germantown, MD, UNITED STATES
Kovacs, Karl F., Rockville, MD, UNITED STATES
Zidanic, Michael, Derwood, MD, UNITED STATES
Jay, Gilbert, North Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096271	A1	20030522
APPLICATION INFO.:	US 2002-195071	A1	20020715 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-930181, filed on 16 Aug 2001, GRANTED, Pat. No. US 6455292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ORIGENE TECHNOLOGIES, INCORPORATED, 6 TAFT COURT, SUITE 100, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	2764		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 13 USPATFULL on STN

TI Full-length serine protein kinase in brain and pancreas

AB The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine, etc. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, especially relating to brain and pancreas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:133951 USPATFULL
TITLE: Full-length serine protein kinase in brain and pancreas
INVENTOR(S): Shu, Youmin, Potomac, MD, UNITED STATES
Fan, Wufang, Germantown, MD, UNITED STATES
Kovacs, Karl F., Rockville, MD, UNITED STATES
Zidanic, Michael, Derwood, MD, UNITED STATES
Jay, Gilbert, North Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092036	A1	20030515
APPLICATION INFO.:	US 2002-195072	A1	20020715 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-930181, filed on 16 Aug 2001, GRANTED, Pat. No. US 6455292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ORIGENE TECHNOLOGIES, INCORPORATED, 6 TAFT COURT, SUITE 100, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		

LINE COUNT: 2773
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 13 USPATFULL on STN

TI Methods for treating diseases and increasing longevity
AB Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or indirect and utilizes energy, enhancement compositions, and/or living organisms to enhance the cells and/or cell products produced by organs and suborgans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:64276 USPATFULL
TITLE: Methods for treating diseases and increasing longevity
INVENTOR(S): Elia, James P., Scottsdale, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003044396	A1	20030306
APPLICATION INFO.:	US 2002-268833	A1	20021010 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-179589, filed on 25 Jun 2002, PENDING Continuation-in-part of Ser. No. US 1998-64000, filed on 21 Apr 1998, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Gerald K. White, Esq., GERALD K. WHITE & ASSOCIATES, P.C., Suite 835, 205 W. Randolph Street, Chicago, IL, 60606		
NUMBER OF CLAIMS:	124		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2697		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 13 USPATFULL on STN

TI Method for growing human organs and suborgans
AB Organogenesis methods, including angiogenesis, are disclosed wherein genetic material, such as a growth factor and a physiological nutrient culture are employed in such process. Also included is another aspect of the invention wherein a physiological medium is used in combination with such genetic material to direct and/or control organogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:336844 USPATFULL
TITLE: Method for growing human organs and suborgans
INVENTOR(S): Elia, James P., Scottsdale, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002192198	A1	20021219
APPLICATION INFO.:	US 2002-179589	A1	20020625 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-64000, filed on 21 Apr 1998, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Gerald K. White, Esq., GERALD K. WHITE & ASSOCIATES, P.C., Suite 835, 205 W. Randolph Street, Chicago, IL, 60606		
NUMBER OF CLAIMS:	158		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2436		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 13 USPATFULL on STN

TI Full-length serine protein kinase in brain and pancreas

AB The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to diseases and conditions, especially relating to brain and pancreas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:246571 USPATFULL

TITLE: Full-length serine protein kinase in brain and pancreas

INVENTOR(S): Shu, Youmin, Potomac, MD, United States

Fan, Wufang, Germantown, MD, United States

Kovacs, Karl F., Rockville, MD, United States

Zidanic, Michael, Derwood, MD, United States

Jay, Gilbert, North Bethesda, MD, United States

PATENT ASSIGNEE(S): OriGene Technologies, Inc, Rockville, MD, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455292	B1	20020924
APPLICATION INFO.:	US 2001-930181		20010816 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Murthy, Ponnathapuachuta		
ASSISTANT EXAMINER:	Ramirez, Delia		
LEGAL REPRESENTATIVE:	Lebovitz, Richard M.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	2617		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 13 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Assaying islet neogenesis associated protein (**INGAP**) for treating diabetes types I and II, comprises determining the amount of labeled **INGAP** molecule bound to antibodies or to a solid support comprising the bound antibodies -

AN ABN84335 DNA DGENE

AB The present sequence is a 5' PCR primer for **DNA encoding** a hamster islet neogenesis associated protein (**INGAP**) peptide (see ABB79543) comprising amino acids 104-118 of the full-length protein. Cloned **INGAP** cDNA was subjected to PCR using 3' (see ABN84334) and 5' primers which introduced XhoI and BglII sites 3' and 5', respectively, of the **INGAP** gene fragment. This allowed insertion of the **INGAP** PCR product into a vector for production of a fusion protein comprising **INGAP** peptide and a marker protein with enzyme activity. The invention provides methods for assaying **INGAP** in a test sample. In a competitive binding assay, antibodies which specifically bind to an **INGAP** immunogen (see ABB79542-45) are contacted with a test sample which may contain **INGAP** protein, and a labelled **INGAP** molecule, e.g. a fusion protein comprising **INGAP** protein and a marker protein with enzymatic activity. The amount of labelled **INGAP** molecule bound to the antibodies is then determined. This amount is inversely related to **INGAP** protein in the test sample. The method can be used to determine the amount of **INGAP** e.g. in culture media or biological tissues and fluids.

The ability to assay **INGAP** will facilitate the full exploitation of this protein for fighting human disease, such as diabetes types I and II.

ACCESSION NUMBER: ABN84335 DNA DGENE
TITLE: Assaying islet neogenesis associated protein (**INGAP**) for treating diabetes types I and II, comprises determining the amount of labeled **INGAP** molecule bound to antibodies or to a solid support comprising the bound antibodies -
INVENTOR: Vinik A I; Taylor-Fishwick D
PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.
PATENT INFO: WO 2002056028 A2 20020718 29p
APPLICATION INFO: WO 2002-US71 20020108
PRIORITY INFO: US 2001-260210P 20010109
US 2002-36418 20020107
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-557841 [59]
DESCRIPTION: Islet neogenesis associated protein (**INGAP**) gene 5' PCR primer.

L3 ANSWER 13 OF 13 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Assaying islet neogenesis associated protein (**INGAP**) for treating diabetes types I and II, comprises determining the amount of labeled **INGAP** molecule bound to antibodies or to a solid support comprising the bound antibodies -
AN ABN84334 DNA DGENE
AB The present sequence is a 3' PCR primer for **DNA encoding** a hamster islet neogenesis associated protein (**INGAP**) peptide (see ABB79543) comprising amino acids 104-118 of the full-length protein. Cloned **INGAP** cDNA was subjected to PCR using 3' and 5' (see ABN84335) primers which introduced XhoI and BglII sites 3' and 5', respectively, of the **INGAP** gene fragment. This allowed insertion of the **INGAP** PCR product into a vector for production of a fusion protein comprising **INGAP** peptide and a marker protein with enzyme activity. The invention provides methods for assaying **INGAP** in a test sample. In a competitive binding assay, antibodies which specifically bind to an **INGAP** immunogen (see ABB79542-45) are contacted with a test sample which may contain **INGAP** protein, and a labelled **INGAP** molecule, e.g. a fusion protein comprising **INGAP** protein and a marker protein with enzymatic activity. The amount of labelled **INGAP** molecule bound to the antibodies is then determined. This amount is inversely related to **INGAP** protein in the test sample. The method can be used to determine the amount of **INGAP** e.g. in culture media or biological tissues and fluids. The ability to assay **INGAP** will facilitate the full exploitation of this protein for fighting human disease, such as diabetes types I and II.

ACCESSION NUMBER: ABN84334 DNA DGENE
TITLE: Assaying islet neogenesis associated protein (**INGAP**) for treating diabetes types I and II, comprises determining the amount of labeled **INGAP** molecule bound to antibodies or to a solid support comprising the bound antibodies -
INVENTOR: Vinik A I; Taylor-Fishwick D
PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.
PATENT INFO: WO 2002056028 A2 20020718 29p
APPLICATION INFO: WO 2002-US71 20020108
PRIORITY INFO: US 2001-260210P 20010109
US 2002-36418 20020107
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-557841 [59]

DESCRIPTION: Islet neogenesis associated protein (INGAP) gene 3'
PCR primer.

=> e VINIK, a/au

E1	7	VINIK R/AU
E2	1	VINIK V V/AU
E3	0 -->	VINIK, A/AU
E4	1	VINIKAINEN J/AU
E5	1	VINIKAITIS G P/AU
E6	2	VINIKAS A A/AU
E7	3	VINIKER D/AU
E8	23	VINIKER D A/AU
E9	2	VINIKHINA L N/AU
E10	6	VINIKKA L/AU
E11	2	VINIKKA LASSE/AU
E12	2	VINIKOFF C/AU

=> e pittenger, g/au

E1	4	PITTENGER V M/AU
E2	1	PITTENGER VICKI M/AU
E3	0 -->	PITTENGER, G/AU
E4	1	PITTENS J J/AU
E5	1	PITTEOLOU R/AU
E6	3	PITTER/AU
E7	3	PITTER A/AU
E8	6	PITTER A F/AU
E9	3	PITTER A F V/AU
E10	1	PITTER ANDREAS/AU
E11	2	PITTER C/AU
E12	2	PITTER D/AU

=> e rafaeloff, r/au

E1	2	RAFAELOFF RAFAEL/AU
E2	10	RAFAELOFF RONIT/AU
E3	0 -->	RAFAELOFF, R/AU
E4	1	RAFAELOV R/AU
E5	1	RAFAELOVICH L/AU
E6	3	RAFAELOVSKY M/AU
E7	1	RAFAELS RAYMOND J/AU
E8	1	RAFAELSEN E/AU
E9	23	RAFAELSEN L/AU
E10	8	RAFAELSEN O/AU
E11	410	RAFAELSEN O J/AU
E12	1	RAFAELSEN OLE J/AU

=> s e4

L4 1 "RAFAELOV R"/AU

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 MEDLINE on STN

TI Insulin resistance in Cushing's syndrome.

AB Insulin resistance is well established in Cushing's syndrome, but its mechanisms are not completely understood. We performed the euglycemic insulin clamp technique on four patients with Cushing's syndrome, five obese patients and five normal volunteers, in order to determine the role of impairments in insulin responsiveness and insulin clearance in hypercorticism and obesity. Insulin was infused at 0.3, 1, 3 and 10 mU/kg/min, and steady-state glucose-infusion rates required to maintain euglycemia were determined. Glucose disposal at maximal insulin levels was 11.9 +/- 0.4 mg/kg/min in normals, with a 29% decrease in obese and a 42% decrease in Cushing's syndrome patients. Half maximally effective insulin concentrations were increased in both abnormal groups compared to

normals. Maximal insulin clearance rates were 1460 +/- 200 ml/min/m2 in normals, not significantly changed in obese and 40% decreased in Cushing's syndrome patients. These results indicate that the insulin resistance in Cushing's syndrome is distinct from that occurring in obesity and is characterized by both decreased insulin responsiveness and decreased insulin clearance. These impairments could be caused by a common defect which may be at or distal to the glucose transport level.

ACCESSION NUMBER: 86057406 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3905556
TITLE: Insulin resistance in Cushing's syndrome.
AUTHOR: Karnieli E; Cohen P; Barzilai N; Ish-Shalom Z; Armoni M; Rafaelov R; Barzilai D
CONTRACT NUMBER: AM 31489 (NIADDK)
SOURCE: Hormone and metabolic research. Hormon- und Stoffwechselforschung. Hormones et metabolisme, (1985 Oct) 17 (10) 518-21.
JOURNAL code: 0177722. ISSN: 0018-5043.
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198601
ENTRY DATE: Entered STN: 19900321
Last Updated on STN: 19990129
Entered Medline: 19860122

=> e rosenberg, l/au

E1	1	ROSENBERG ZVI/AU
E2	3	ROSENBERG ZVIKA/AU
E3	0 -->	ROSENBERG, L/AU
E4	1	ROSENBERGE B/AU
E5	1	ROSENBERGE C/AU
E6	1	ROSENBERGE C T/AU
E7	1	ROSENBERGE D/AU
E8	4	ROSENBERGE E C/AU
E9	3	ROSENBERGE E D/AU
E10	3	ROSENBERGE G/AU
E11	2	ROSENBERGE G J/AU
E12	10	ROSENBERGE H/AU

=> e duguid, w/au

E1	18	DUGUID WILLIAM P/AU
E2	1	DUGUID WILLIAM RICHARDSON/AU
E3	0 -->	DUGUID, W/AU
E4	2	DUGUIES M V/AU
E5	1	DUGUINE OLIVIER/AU
E6	1	DUGULESCU P/AU
E7	1	DUGUM JELENA/AU
E8	1	DUGUM MIRSAID/AU
E9	1	DUGUM N/AU
E10	20	DUGUMA B/AU
E11	3	DUGUMA BAHIRU/AU
E12	5	DUGUMA G/AU

Refine Search

Search Results -

Terms	Documents
L3 and L2	3

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L4

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Saturday, August 14, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT; PLUR=YES; OP=OR

<u>L4</u>	L3 and l2	3	<u>L4</u>
<u>L3</u>	pittenger.in.	74	<u>L3</u>
<u>L2</u>	vinik.in.	4	<u>L2</u>
<u>L1</u>	INGAP with DNA	4	<u>L1</u>

END OF SEARCH HISTORY

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS				

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 5840531 A

L4: Entry 1 of 3

File: USPT

Nov 24, 1998

US-PAT-NO: 5840531

DOCUMENT-IDENTIFIER: US 5840531 A

TITLE: Ingap protein involved in pancreatic islet neogenesis

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Vinik</u> ; Aaron I.	Norfolk	VA		
<u>Pittenger</u> ; Gary L.	Virgina Beach	VA		
Rafaeloff; Ronit	Chesapeake	VA		
Rosenberg; Lawrence	Montreal			CA
Duguid; William P.	Montreal			CA

US-CL-CURRENT: 435/69.1; 424/185.1, 435/252.3, 536/23.1, 536/23.5, 536/24.3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	RIIAC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	---------

☐ 2. Document ID: US 5834590 A

L4: Entry 2 of 3

File: USPT

Nov 10, 1998

US-PAT-NO: 5834590

DOCUMENT-IDENTIFIER: US 5834590 A

**** See image for Certificate of Correction ****

TITLE: Ingap protein involved in pancreatic islet neogenesis

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Vinik</u> ; Aaron I.	Norfolk	VA		
<u>Pittenger</u> ; Gary L.	Virginia Beach	VA		
Rafaeloff; Ronit	Norfolk	VA		
Rosenberg; Lawrence	Montreal			CA

h e b b g e e e f e h e f b e

Duguid; William P.

Montreal

CA

US-CL-CURRENT: 530/350; 424/198.1, 435/69.7, 530/412

Full	Title	Citation	Front	Review	Classification	Date	Reference	Attachments	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 5804421 A

L4: Entry 3 of 3

File: USPT

Sep 8, 1998

US-PAT-NO: 5804421

DOCUMENT-IDENTIFIER: US 5804421 A

TITLE: High level of expression of ingap in bacterial and eukaryotic cells

DATE-ISSUED: September 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Vinik</u> ; Aaron I.	Norfolk	VA		
<u>Pittenger</u> ; Gary L.	Virginia Beach	VA		
Rafaeloff-Phail; Ronit	Chesapeake	VA		
Barlow; Scott W.	Norfolk	VA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 530/350, 536/23.1, 536/23.5,
536/24.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Attachments	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-------------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L3 and L2	3

Display Format: [Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS				

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 6593148 B1

L1: Entry 1 of 4

File: USPT

Jul 15, 2003

US-PAT-NO: 6593148

DOCUMENT-IDENTIFIER: US 6593148 B1

TITLE: Cyanine dye compounds and labeling methods

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Narayanan; Narasimhachari	Lincoln	NE		

US-CL-CURRENT: 436/546; 435/6, 436/800, 530/391.3, 530/404, 530/405

Full	Title	Citation	Front	Review	Classification	Date	Reference	Examination	Administrative	Claims	KMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-------------	----------------	--------	-----	----------

☐ 2. Document ID: US 6086737 A

L1: Entry 2 of 4

File: USPT

Jul 11, 2000

US-PAT-NO: 6086737

DOCUMENT-IDENTIFIER: US 6086737 A

TITLE: Sequencing near infrared and infrared fluorescence labeled DNA for detecting using laser diodes and suitable labels therefor

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Patonay; Gabor	Conyers	GA		
Narayanan; Narasimhachari	Lincoln	NE		
Brumbaugh; John A.	Lincoln	NE		
Middendorf; Lyle Richard	Lincoln	NE		

US-CL-CURRENT: 204/461; 204/452, 204/456, 204/603, 204/606, 204/612, 435/968, 436/800, 536/25.32

Full	Title	Citation	Front	Review	Classification	Date	Reference	Examination	Administrative	Claims	KMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-------------	----------------	--------	-----	----------

☐ 3. Document ID: US 5840531 A

L1: Entry 3 of 4

File: USPT

Nov 24, 1998

US-PAT-NO: 5840531

DOCUMENT-IDENTIFIER: US 5840531 A

TITLE: Ingap protein involved in pancreatic islet neogenesis

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vinik; Aaron I.	Norfolk	VA		
Pittenger; Gary L.	Virginia Beach	VA		
Rafaeloff; Ronit	Chesapeake	VA		
Rosenberg; Lawrence	Montreal			CA
Duguid; William P.	Montreal			CA

US-CL-CURRENT: 435/69.1; 424/185.1, 435/252.3, 536/23.1, 536/23.5, 536/24.3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Drawings	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	----------	--------	------	----------

☐ 4. Document ID: US 5834590 A

L1: Entry 4 of 4

File: USPT

Nov 10, 1998

US-PAT-NO: 5834590

DOCUMENT-IDENTIFIER: US 5834590 A

**** See image for Certificate of Correction ****

TITLE: Ingap protein involved in pancreatic islet neogenesis

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vinik; Aaron I.	Norfolk	VA		
Pittenger; Gary L.	Virginia Beach	VA		
Rafaeloff; Ronit	Norfolk	VA		
Rosenberg; Lawrence	Montreal			CA
Duguid; William P.	Montreal			CA

US-CL-CURRENT: 530/350; 424/198.1, 435/69.7, 530/412

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Drawings	Claims	KWIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
INGAP with DNA	4

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

?us5840531/pn

?us5840531/pn

** SS 2: Results 1

Search statement 3

?prt full legalall max

1/1 PLUSPAT - (C) QUESTEL-ORBIT- image

CPIM Questel-Orbit

PN - US5840531 A 19981124 [US5840531]

TI - (A) Ingap protein involved in pancreatic islet neogenesis

PA - (A) MCGILL UNIVERSITY (CA); EASTERN VIRGINIA MEDICAL SCHOOL (US)

PA0 - McGill University, [CA]

- Eastern Virginia Medical School of the Medicine College of Hampton Roads, Norfolk VA [US]

IN - (A) VINIK AARON I (US); PITTENGER GARY L (US); RAFAELOFF RONIT (US); ROSENBERG LAWRENCE (CA); DUGUID WILLIAM P (CA)

AP - US70966296 19960909 [1996US-0709662]

FD - C.I.P. of US401530 19950222 [1995US-0401530]

PR - US627195P 19951107 [1995US-P006271]

- US40153095 19950222 [1995US-0401530]

- US70966296 19960909 [1996US-0709662]

IC - (A) C12N-015/00

EC - C07K-014/47A22

- C07K-014/47A27

ICO - M07K-201/00

- M07K-203/00

- M07K-205/00

- M07K-207/00

- M07K-211/00

- M07K-215/00

- M07K-217/00

PCL - ORIGINAL (O) : 435069100; CROSS-REFERENCE (X) : 424185100 435252300
536023100 536023500 536024300

DT - Corresponding document

CT - US4965188

- Lu et al. (1996) Nature, vol. 380, pp. 544-547.

Dagorn et al. (1995) Accession No. Q69201, GenBank Database.

Hillier et al. (1996) Accession No. AA034395, EST database.

Hillier et al. (1995) Accession No. H20422, EST database.

Stein et al., "Antisense Oligonucleotides as Therapeutic Agents --Is the let Really Magical?", Science 261:1004-1012 (1993).

Bradley et al., "BioTechnology. Modifying the Mouse", Design and Desire 10:534-539 (1992).

Miller et al., "Human Gene Therapy Comes of Age", Nature 357:455-460 (1992).

Watanabe et al., "Pancreatic Beta-Cell Replication and Amelioration of

Surgical Diabetes by Reg Protein", Proc. Natl. Acad. Sci. USA 91:3589-3592 (1994).

Liang et al., "Distribution and Cloning of Eukaryotic mRNAs by Means of Differential Display: Refinements and Optimization", Nucleic Acids Research 21(14):3269-3275 (1993).

Rosenberg et al., "Reversal of Diabetes by the Induction of Islet Cell Neogenesis", Transplantation Proceedings 24(3):1027-1028 (1992).

Rouquier et al., "Rat Pancreatic Stone Protein Messenger RNA", J. Biol. Chem., 266(2):786-791 (1991).

Lasserre et al., "A Novel Gene (HIP) Activated in Human Primary Liver Cancer", Cancer Research 52:5089-5095 (1992).

Terazono et al., "A Novel Gene Activated in Regenerating Islets", J. Biol. Chem., 263(5):211-2114 (1988).

Vinik et al., "Factors Controlling Pancreatic Islet Neogenesis", Yale Journal of Biology and Medicine 65:471-491 (1992).

Orelle et al., "Human Pancreatitis-associated Protein" J. Clin. Invest. 90:2284-2291 (1992).

STG - (A) United States patent

AB - Cellophane wrapping (CW) of hamster pancreas induces proliferation of duct epithelial cells followed by endocrine cell differentiation and islet neogenesis. Using the mRNA differential display technique a cDNA clone expressed in cellophane wrapped but not in control pancreata was identified. Using this cDNA as a probe, a cDNA library was screened and a gene not previously described was identified and named INGAP.

1/1 LGST - (C) EPO

PN - US5840531 A 19981124 [US5840531]

AP - US70966296 19960909 [1996US-0709662]

ACT - 19970320 US/AS02-A

ASSIGNMENT OF ASSIGNOR'S INTEREST

OWNER: MCGILL UNIVERSITY 845 SHERBROKE STREET WEST MONTRE; EFFECTIVE DATE: 19970226

- 19970320 US/AS02-A

ASSIGNMENT OF ASSIGNOR'S INTEREST

OWNER: ROSENBERG, LAWRENCE; EFFECTIVE DATE: 19970226

- 19970320 US/AS02-A

ASSIGNMENT OF ASSIGNOR'S INTEREST

OWNER: DUGUID, WILLIAM P.; EFFECTIVE DATE: 19970226

UP - 2003-22

1/1 CRXX - (C) CLAIMS/RRX

AN - 3075996

PN - 5,840,531 A 19981124 [US5840531]

PA - Eastern Virginia Medical Authority; McGill Univ, Royal Inst for the Advancement of Learning CA

PT - C (Chemical)

ACT - 20010924 REASSIGNED

ASSIGNMENT OF ASSIGNOR'S INTEREST

Assignor: VINIK, AARON I. DATE SIGNED: 07/18/2001
PITTENGER, GARY L. DATE SIGNED: 07/18/2001
RAFAELOFF, RONIT DATE SIGNED: 08/14/2001

Assignee: EASTERN VIRGINIA MEDICAL SCHOOL OF THE MEDICINE COLLEGE OF
HAMPTON ROADS P.O. BOX 1980 NORFOLK, VIRGINIA 23501-198

Reel 012188/Frame 0472

Contact: BANNER & WITCOFF SARAH A. KAGAN 1001 G STREET, N.W. 11TH
FLOOR WASHINGTON, DC 20001

UP - 2002-03
URAS- 2002-01-15

Search statement 3